Healthineers Wins Fresh Analyst Support as €700 Million Savings Plan Meets a Softer 2027 Profit Guide

Barclays lifted its price target on Siemens Healthineers from EUR 47.50 to EUR 51 on Monday while reaffirming its "Overweight" rating — one of several bullish revisions that landed as the medical technology group pushes ahead with a sweeping overhaul of its diagnostics arm.

Goldman Sachs raised its own target from EUR 43 to EUR 49 that same day, keeping a "Neutral" stance, and a third research house moved its objective from EUR 50 to EUR 55 while restating a buy recommendation. The shares, however, slipped 0.4% in the session after already ceding ground at times in Xetra trading a day earlier.

Carve-out and cost cuts in the same package

At the heart of the restructuring is the in-vitro diagnostics business, which Siemens Healthineers began carving out on 5 November. The unit is to be built up step by step as a standalone organisation trading under the name Olyrian Diagnostics, with the separation slated for completion by mid-2028. During the transition it remains part of the parent company.

Reuters reported the same day that the company plans additional savings of EUR 400 million at Diagnostics, alongside at least EUR 300 million in the core business — measures that could also affect jobs.

Shareholders will get a direct vote on the split in February 2027. A rebranding is on the table too: Siemens Healthineers intends to adopt the name Healthineers, with the brand and legal-name transition set to begin after the planned deconsolidation of Siemens and to run over three years. The change requires approval at the annual general meeting.

The numbers behind the caution

Those announcements give the overhaul a concrete financial dimension, but they land against a profit outlook that points the other way. In the completed fiscal year 2026, Siemens Healthineers posted comparable revenue growth of 4.0% and adjusted undiluted earnings per share of EUR 2.42.

For fiscal 2027, management projects comparable revenue growth of 4.0–5.0% and adjusted undiluted EPS of EUR 2.20–2.40. Even the top of that range sits below the year just closed — a forecast that describes continued top-line expansion paired with a thinner bottom line.

That gap is what makes the savings programme the pivotal variable. Cost discipline alone, at the announced magnitude, does not settle the question of economic success; what matters is whether the cuts can be shown to stabilise earnings. Neither the new name nor the organisational reshuffle substitutes for that proof.

What the annual report must show

The next hard checkpoint is the annual report scheduled for 25 November 2026. Until then, investors face a choice between trusting the cost reductions and holding back in light of the lower profit guidance.

The constructive case rests on the company delivering the savings while holding its growth trajectory, which would let shareholders read the weaker earnings guidance as a transitional phase. A standalone setup could make it easier to assess each business on its own merits — provided the report lays out the prospects of both the remaining activities and diagnostics in a way that can be verified.

The cautious case is a prolonged gap between revenue growth and profit development, made heavier if the savings arrive later than expected or fall short of their intended effect. Then valuation would have to lean more heavily on the lower earnings base. The possible job consequences reported by Reuters underline the operational weight of a programme of this scale — it demands execution in the day-to-day business, not just an announcement.

For now, the yardstick stays clear: the revamp gains conviction if announced savings turn into a more resilient earnings outlook. The annual report, and then the February 2027 vote on the spin-off, are the dates on which that case will be tested.